Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 607-858-0 | CAS number: 260781-16-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1994-01-25 to 1994-07-06
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 994
- Report date:
- 1994
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Version / remarks:
- 1981-05-12
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.7 (Repeated Dose (28 Days) Toxicity (Oral))
- Version / remarks:
- 1992
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- signed 1994-03-16
- Limit test:
- no
Test material
- Reference substance name:
- 1-[({[(1R,2S,5R)-5-methyl-2-(propan-2-yl)cyclohexyl]oxy}carbonyl)oxy]propan-2-ol
- EC Number:
- 607-858-0
- Cas Number:
- 260781-16-6
- Molecular formula:
- C14H26O4
- IUPAC Name:
- 1-[({[(1R,2S,5R)-5-methyl-2-(propan-2-yl)cyclohexyl]oxy}carbonyl)oxy]propan-2-ol
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Remarks:
- CD
- Details on species / strain selection:
- The rat was selected for this study as it is a readily available rodent species historically used in safety evaluation studies and is acceptable to appropriate regulatory authorities.
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River (U.K.) Limited, Manston, Kent
- Age at start of treatment: approx. six to seven weeks old
- Weight at start of treatment: males: 183 g to 230 g; females: 159 g to 191 g
- Housing: housed in groups of five by sex in polypropylene grid-floor cages suspended over trays lined with absorbent paper.
- Diet (ad libitum): pelleted diet (Rat and Mouse SQC Expanded Diet No. 1)
- Water (ad libitum): mains water
- Acclimation period: fourteen days
DETAILS OF FOOD AND WATER QUALITY:
The diet and drinking water were considered not to contain any contaminant at a level that might have affected the purpose or integrity of the study.
ENVIRONMENTAL CONDITIONS
- Temperature: 20 - 23 °C
- Relative humidity: 28 - 69 %.
- Air changes: at least fifteen air changes/hour
- Photoperiod (hrs dark / hrs light): 12/12
Administration / exposure
- Route of administration:
- oral: gavage
- Details on route of administration:
- The oral route was selected by the study sponsor as a possible route of human exposure and the results of the study are believed to be of value in predicting the likely toxicity of the test material to man.
- Vehicle:
- arachis oil
- Remarks:
- B.P. (British Pharmacopoeias)
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS:
The test material was prepared at the appropriate concentrations as a solution in the vehicle. Formulations were prepared weekly and stored at 4°C in the dark.
The volume of test and control material administered to each animal was based on the most recent bodyweight and was adjusted at weekly intervals. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- The stability, homogeneity, and concentration of the test material formulations were analysed. The test item concentration in the test samples was determined by gas chromatography using an external standard technique.
For homogeneity determination, the test material formulations were mixed thoroughly and samples were taken from the top, middle and bottom of the container shaking in between sampling. The sampling was performed in triplicate.
For stability determination, the test material formulations were sampled and analysed initially and then after stroage at approximately 4 °C in the dark for ten days.
For the verification of the test material formulation concentration, the test material formulations were sampled and analysed within three days of preparation.
Results:
The formulation showed to be stable for at least ten days. In addition the results indicated that the prepared formulations were within ± 11 % of the nominal concentration. - Duration of treatment / exposure:
- 28 consecutive days
- Frequency of treatment:
- daily
Doses / concentrationsopen allclose all
- Dose / conc.:
- 15 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 150 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 1 000 mg/kg bw/day (actual dose received)
- No. of animals per sex per dose:
- Main groups: 5 males / 5 females
Recovery groups (vehicle control recovery and 1000 mg/kg bw/day recovery group): 5 males / 5 females - Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale:
The dose levels for the 28-day repeated dose toxicity study were chosen based on the results of a range-finding study. In the range finding study groups of 3 male and 3 female Sprague-Dawley CD strain rats were dosed with either 150, 400, or 1000 mg/kg bw/day of the test item in arachis oil B.P. by gavage for a duration of 14 consecutive days. A vehicle control group was run concurrently. The following parameters were examined/recorded: clinical signs, mortality, body weight, and gross pathology.
Results:
Mortality:
There were no deaths during the study.
Clinical signs:
150, 400. or 1000 mg/kg bw/day: animals treated with the test material showed short-lived increased salivation immediately after dosing from Day 3 onwards.
1000 mg/kg bw/day: isolated incidents of more prolonged increased salivation were observed from Day 9. Associated findings of fur wetting and/or red/brown staining around the mouth were also observed on isolated occasions during the study.
400 mg/kg bw/day: one animal showed red/brown staining around the mouth
Body weight:
Animals treated with the test material showed similar body weight gains to controls during the study.
Gross pathology:
No macroscopic abnormalities were seen at terminal kill.
The dose levels for the main twenty-eight day study were chosen, following consultation with the sponsor, as: 15, 150, and 1000 mg/kg bw/day plus a control group treated with vehicle only.
- Post-exposure recovery period in satellite groups: 14 days - Positive control:
- no data
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule (treatment period): immediately before dosing and one and five hours after dosing during the working week or immediately before dosing and one hour after dosing at weekends.
- Time schedule (treatment-free period): twice daily, morning and afternoon (once daily at weekends and on public holidays).
- Cage side observations checked: overt signs of toxicity, ill-health or behavioural change
DETAILED CLINICAL OBSERVATIONS: No
BODY WEIGHT: Yes
- Time schedule for examinations (treatment period): Day 0 (the day before the start of treatment) and on Days 7, 14, 21 and 28
- Time schedule for examinations (treatment-free period): Days 35 and 42
Body weights were also recorded at necropsy.
FOOD CONSUMPTION AND COMPOUND INTAKE:
- Food consumption for each group determined and mean weekly diet consumption calculated as g food/kg body weight/week: Yes
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: No
FOOD EFFICIENCY:
- Change in mean bodyweight (g)/ mean food consumption (g/rat/week): Yes
WATER CONSUMPTION AND COMPOUND INTAKE: Yes
- Time schedule for examinations: daily from Day 8 onwards
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: Yes
- Time schedule for collection of blood: animals from the treatment groups at the end of the treatment period (Day 28) and satellite group animals at the end of the treatment-free period (Day 42).
- Anaesthetic used for blood collection: No
- Animals fasted: No
- How many animals: all animals from the treatment groups and recovery groups
- Parameters checked: haematocrit, haemoglobin, erythrocyte count, total leucocyte count, differential leucocyte count, platelet count, mean corpuscular haemoglobin, mean corpuscular volume, mean corpuscular haemoglobin concentration, and clotting time
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: animals from the treatment groups at the end of the treatment period (Day 28) and satellite group animals at the end of the treatment-free period (Day 42).
- Animals fasted: No
- How many animals: all animals from the treatment groups and recovery groups
- Parameters checked: blood urea, total protein, albumin, albumin/globulin ratio (by calculation), sodium, potassium, chloride, calcium, inorganic phosphorus, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, glucose, total bilirubin, and creatinine
URINALYSIS: No
NEUROBEHAVIOURAL EXAMINATION: No
IMMUNOLOGY: No - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
HISTOPATHOLOGY: Yes
On completion of the dosing period or, in the case of satellite group animals, at the end of the treatment-free period; all animals were killed.
Gross pathology:
All animals were subjected to a full external and internal examination, and any macroscopic abnormalities were recorded.
Organ weights:
The following organs from animals that were killed at the end of the study, dissected free from fat, were weighed before fixation: adrenals, brain, gonads, heart, kidneys, liver, pituitary, and spleen.
Histopathology:
Samples of the following tissues were removed from all animals and preserved: adrenals, aorta (thoracic), bone & bone marrow (femur), bone & bone marrow (sternum), brain, caecum, colon, duodenum, eyes, gross lesions, heart, ileum, jejunum, kidneys, liver, lungs, lymph nodes (cervical and mesenteric), muscle (skeletal), oesophagus, ovaries, pancreas, pituitary, prostate, rectum, salivary glands, sciatic nerve, seminal vesicles, skin (hind limb), spleen, stomach, testes, thymus, thyroid/parathyroid, trachea, urinary bladder, and uterus.
The following preserved tissues from all animals (treatment groups, recovery groups, and control groups) were prepared as paraffin blocks, sectioned (5 µm) and stained for microscopic examination:
adrenals, spleen, heart, kidneys, liver, and testes. Macroscopically observed lesions were also processed.
Initially, microscopic examination was performed on control and 1000 mg/kg bw/day dose groups of the treatment period only but since there were indications of treatment-related renal changes, examination was subsequently extended to include sections of kidneys from all animals in the remaining dose groups. - Statistics:
- Data were processed to give group mean values and standard deviations where appropriate.
Absolute and relative organ weights, haematological and blood chemical data were analysed by one way analysis of variance incorporating 'F-max' test for homogeneity of variance. Data showing heterogeneous variances were analysed using Kruskal Wallis non-parametric analysis of variance and Mann Whitney U-Test.
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- no effects observed
- Water consumption and compound intake (if drinking water study):
- effects observed, treatment-related
- Description (incidence and severity):
- 1000 mg/kg bw/day: animals of either sex showed a slightly greater water intake than controls during the study, which regressed in satellite high dose animals immediately upon cessation of treatment.
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- 1000 mg/kg bw/day: males showed a slight but statistically significant increase in plasma potassium and calcium levels compared with controls together with a slight reduction in plasma chloride concentration. Differences between the plasma electrolyte levels of test and control animals were no longer evident amongst satellite group animals following a further fourteen days without treatment.
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- Liver:
1000 mg/kg bw/day: animals of either sex showed a statistically significant increase in liver weight, both absolute and relative to body weight, compared with controls with several of the individual values outside the normally expected ranges for rats of the strain and age used in the study. Increased liver weights were no longer evident in satellite animals following a further fourteen days without treatment. - Gross pathological findings:
- no effects observed
- Neuropathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- not examined
- Other effects:
- not examined
- Details on results:
- CLINICAL SIGNS:
15 mg/kg bw/day: animals showed no clinically observable abnormalities during the study.
150 mg/kgbw/day: two animals (1 female / 1 male) showed short-lived increased salivation immediately after' dosing on Days 13 and 14 respectively.
One female showed evidence of minor physical damage around the mouth during the final week of dosing but this isolated finding showed no dose-relationship and, as such, was considered not to be indicative of test material toxicity.
1000 mg/kg bw/day: animals of either sex showed short-lived increased salivation either before or immediately after dosing from Day 3 onwards together with associated findings of fur wetting, red/brown staining around the mouth and, on two isolated occasions, noisy respiration and red/brown staining of the fur. More persistent increased salivation was also seen intermittently at this dose level from Day 5. Satellite high dose animals showed no clinical signs following cessation of treatment.
One satellite high dose female had a distended abdomen, confined to the left side of the body, from Day 8 onwards. The condition persisted throughout the fourteen day recovery period with the animal showing a further slight deterioration in health from Day 37, also appearing emaciated. No gastrointestinal tract abnormality was recorded at necropsy and the change in appearance was considered not to be associated with test material toxicity.
MORTALITY:
15, 150, and 1000 mg/kg bw/day: no deaths
BODY WEIGHT:
15, 150, and 1000 mg/kg bw/day: all animals showed normal body weight development during the study.
Animals treated with test material showed similar body weight gains to controls over the treatment period.
FOOD CONSUMPTION:
15, 150, and 1000 mg/kg bw/day: no adverse effect on food consumption during the study.
FOOD EFFICIENCY:
15, 150, and 1000 mg/kg bw/day: animals treated with the test material showed similar weekly food efficiences to controls.
WATER CONSUMPTION:
15 and 150 mg/kg bw/day: water intake was unaffected by treatment
HAEMATOLOGY:
15, 150, and 1000 mg/kg bw/day: no treatment-related changes in the haematological parameters measured
1000 mg/kg bw/day: males showed a slight but statistically significant increase in mean corpuscular volume compared with controls but all individual values were within the normally expected range for rats of the strain and age used in the study and this intergroup difference was considered to be fortuitous. Satellite females had a higher neutrophil count than controls at the end of the fourteen day recovery period but in the absence of a similar finding at the end of the twenty-eight day dosing period, this difference between test and control animals was considered not to be toxicologically significant.
15 and 150 mg/kg bw/day: the remaining statistically significant intergroup differences were confined to an increased platelet count. These findings were not dose-related and were considered not to be treatment-related.
CLINICAL CHEMISTRY:
1000 mg/kg bw/day dose group females and animals from the 15 and 150 mg/kg bw/day dose groups showed no treatment-related changes in the blood chemical parameters measured.
1000 mg/kg bw/day: females showed a slight but statistically significant increase in plasma glucose concentration compared with controls but none of the individual values were unusually high for rats of the strain and age used in the study and this finding was considered not to be toxicologically significant. Satellite females showed a lower plasma urea concentration than controls after a further fourteen days without treatment together with a higher plasma bilirubin level. Again, none of the individual values were outside the normally expected range for rats of the strain and age used and as neither parameter was
affected by treatment at the end of the twenty-eight day dosing period, the intergroup differences were considered to have arisen fortuitously.
The remaining statistically significant intergroup differences were confined to an increase in plasma calcium and creatinine levels in 150 mg/kg bw/day dose group females. These findings were not dose-related and, as such, were considered not to be toxicologically significant.
ORGAN WEIGHTS:
15 and 150 mg/kg bw/day: no treatment-related organ weight changes
1000 mg/kg bw/day: males showed a slight increase in absolute and relative kidney weight compared with controls and although the intergroup difference in relative kidney weight failed to achieve statistical significance and none of the individual values were abnormally high for rats of the strain and age used, relative kidney weight remained slight elevated (statistically significant) amongst satellite males at the end of the fourteen day recovery period. These findings may be associated with the morphological renal changes detected at this dose level.
1000 mg/kg bw/day: males and females showed a slight but statistically significant reduction in relative heart and spieen weight respectively. None of the individual values were outside the normally expected ranges for rats of the strain and age used in the study and, in the absence of any histopathological evidence of either myocardial or splenic changes, these intergroup differences were considered not to be toxicologically significant.
The remaining statistically significant intergroup differences were confined to a reduced relative brain weight for 15 and 1000 mg/kg bw/day dose group females and a reduction in relative heart and kidney weight for 150 mg/kg/day dose group females. These findings showed no dose relationship and were considered not to be toxicologically important.
GROSS PATHOLOGY:
15, 150, and 1000 mg/kg bw/day: macropscopic kidney changes were observed at terminal kill.
1000 mg/kg bw/day: with the exception of one female, all animals had speckled kidneys at necropsy which were often also pale compared with those of control animals. Furthermore, slightly speckled kidneys were still evident for several satellite animals following a further fourteen days without treatment.
150 mg/kg bw/day: speckled kidneys were observed for all males and one female from this dose group
15 mg/kg bw/day: speckled kidneys were apparent for three animals (1 male / 2 females).
1000 mg/kg bw/day: the liver of four satellite females was also speckled at the end of the fourteen day recovery period but the toxicological significance of this finding is dubious as a similar macroscopic liver change was not detected at the end of the twenty-eight day dosing period.
Hydronephrosis was identified in two animals at terminal kill but this represents a normally-expected, low incidence finding in laboratory maintained rats of the strain and age used and, as such, was considered not to be toxicologically significant.
HISTOPATHOLOGY:
150 and 1000 mg/kg bw/day: treatment-related renal changes were observed. Globules of eosinophilic material were observed in the proximal tubular epithelium of male rats. Female rats were unaffected. Accumulations of eosinophilic material were also observed amongst satellite 1000 mg/kg bw/day male rats although the reduced severity and incidence indicated some regression of the condition following an additional fourteen days without treatment.
All remaining morphological changes were those commonly observed in laboratory maintained rats of the age and strain employed and, since there were no differences in incidence or severity between control and treatment groups, all were considered to be without toxicological significance.
Effect levels
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 150 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- organ weights and organ / body weight ratios
Target system / organ toxicity
- Critical effects observed:
- not specified
Applicant's summary and conclusion
- Conclusions:
- After the oral administration of 15, 150, or 1000 mg/kg bw/day of the test item no deaths occurred during the study. Furthermore, no treatment-releated effects were observed for clinical signs, body weight and weight changes, food consumption, food efficiency, and haematology.
During necrospy, speckled kidneys were apparent for one male and two female rats of the 15 mg/kg bw/day dose level and in all males and one female of the 150 mg/kg bw/day dose level group. Globules of eosinophilic material were observed in the proximal tubular epithelium of male rats of the 150 mg/kg bw/day dose group.
At the 1000 mg/kg bw/day dose level, animals of either sex showed a statistically significant increase in relative and absolute liver weight. Increased liver weights were no longer evident in satellite animals following a further fourteen days without treatment. Male animals showed a slight increase in absolute and relative kidney weight compared with controls and although the intergroup difference in relative kidney weight failed to achieve statistical significance and none of the individual values were abnormally high for rats of the strain and age used, relative kidney weight remained slightly elevated (statistically significant) amongst satellite males at the end of the fourteen day recovery period. These findings may be associated with the morphological renal changes detected at this dose level. In addition, at the 1000 mg/kg bw/day dose level, macroscopic kidney changes were observed at terminal kill. With the exception of one female, all animals had speckled kidneys at necropsy which were often also pale compared with those of control animals. Furthermore, slightly speckled kidneys were still evident for several satellite animals following a further fourteen days without treatment. Also, at this high dose level, treatment-related renal changes were observed. Globules of eosinophilic material were observed in the proximal tubular epithelium of male rats. Females were unaffected. Accumulations of eosinophilic material were also observed amongst satellite 1000 mg/kg bw/day male rats although the reduced severity and incidence indicated some regression of the condition following an additional fourteen days without treatment. Lastly, the results of 1000 mg/kg/day dose level showed that animals of either sex had a slightly greater water intake than controls during the study, which regressed in satellite high dose animals immediately upon cessation of treatment and that males showed a slight but statistically significant increase in plasma potassium and calcium levels compared with controls together with a slight reduction in plasma chloride concentration. Differences between the plasma electrolyte levels of test and control animals were no longer evident amongst satellite group animals following a further fourteen days without treatment.
Based on the organ weights of liver, a No Observed Adverse Effect Level (NOAEL) for test item of 150 mg/kg bw/day was concluded for males and females. - Executive summary:
A repeated dose oral toxicity study was performed with the test item according to the OECD guideline 407 (1981). The test material was administered by gavage to three groups, each of five male and five female Sprague-Dawley CD strain rats, for twenty-eight consecutive days, at dose levels of 15, 150 and 1000 mg/kg bw/day. A control group of five males and five females was dosed with vehicle alone (arachis oil B.P.). Two satellite groups, each of five males and five females, were treated with the high dose (1000 mg/kg bw/day) or the vehicle alone throughout the twenty-eight day study period and then maintained without treatment for a further fourteen days. The following parameters were evaluated: clinical signs, body weight, food consumption, food efficiency, water consumption, haematology, clinical chemistry, organ weights, macroscopic examination, and histopathology of selected tissues.
After the oral administration of 15, 150, or 1000 mg/kg bw/day of the test item no deaths occurred during the study. Furthermore, no treatment-releated effects were observed for clinical signs, body weight and weight changes, food consumption, food efficiency, and haematology.
During necrospy, speckled kidneys were apparent for one male and two female rats of the 15 mg/kg bw/day dose level and in all males and one female of the 150 mg/kg bw/day dose level group. Globules of eosinophilic material were observed in the proximal tubular epithelium of male rats of the 150 mg/kg bw/day dose group.
At the 1000 mg/kg bw/day dose level, animals of either sex showed a statistically significant increase in relative and absolute liver weight. Increased liver weights were no longer evident in satellite animals following a further fourteen days without treatment. Male animals showed a slight increase in absolute and relative kidney weight compared with controls and although the intergroup difference in relative kidney weight failed to achieve statistical significance and none of the individual values were abnormally high for rats of the strain and age used, relative kidney weight remained slightly elevated (statistically significant) amongst satellite males at the end of the fourteen day recovery period. These findings may be associated with the morphological renal changes detected at this dose level. In addition, at the 1000 mg/kg bw/day dose level, macroscopic kidney changes were observed at terminal kill. With the exception of one female, all animals had speckled kidneys at necropsy which were often also pale compared with those of control animals. Furthermore, slightly speckled kidneys were still evident for several satellite animals following a further fourteen days without treatment. Also, at this high dose level, treatment-related renal changes were observed. Globules of eosinophilic material were observed in the proximal tubular epithelium of male rats. Females were unaffected. Accumulations of eosinophilic material were also observed amongst satellite 1000 mg/kg bw/day male rats although the reduced severity and incidence indicated some regression of the condition following an additional fourteen days without treatment. Lastly, the results of 1000 mg/kg/day dose level showed that animals of either sex had a slightly greater water intake than controls during the study, which regressed in satellite high dose animals immediately upon cessation of treatment and that males showed a slight but statistically significant increase in plasma potassium and calcium levels compared with controls together with a slight reduction in plasma chloride concentration. Differences between the plasma electrolyte levels of test and control animals were no longer evident amongst satellite group animals following a further fourteen days without treatment.
Based on the organ weights of liver, a No Observed Adverse Effect Level (NOAEL) for test item of 150 mg/kg bw/day was concluded for males and females.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.